REG - J.P. Morgan SE - Stabilisation Notice

Deutsche Bank AGAnnouncement

27/04/2023 19:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230427:nRSa7738Xa&default-theme=true

RNS Number : 7738X  J.P. Morgan SE   27 April 2023

27(th) April 2023

Not for distribution, directly or indirectly, in or into the United States or
any jurisdiction in which such distribution would be unlawful.

Cheplapharm Arzneimittel GmbH

Post-stabilisation Period Announcement

Further to the pre-stabilisation period announcement dated 26(th) April 2023,
J.P. Morgan SE, (Marc Lewell - contact +44 207 1342468) hereby gives notice
that no stabilisation (within the meaning of Article 3.2(d) of the Market
Abuse Regulation (EU/596/2014) or the rules of the Financial Conduct
Authority) was undertaken by the Stabilisation Manager(s) named below in
relation to the offer of the following securities.

 Issuer:                    Cheplapharm Arzneimittel GmbH
 Guarantor (if any):        N/A
 Aggregate nominal amount:  EUR 425mm - Fixed rate notes

                            EUR 325mm - Floating rate notes
 Description:               7YR EUR FXD rate notes

                            7YR EUR FRN rate notes

                            Listing : Official List of The International Stock Exchange
 Stabilisation Manager(s):  J.P. Morgan SE (Stabilisation coordinator)

                            Barclays (Stabilisation manager)

                            Deutsche Bank (Stabilisation manager)

 Offer price:               EUR 425mm - 100%

                            EUR 325mm - 99.00%

 

This announcement is for information purposes only and does not constitute an
invitation or offer to underwrite, subscribe for or otherwise acquire or
dispose of any securities of the Issuer in any jurisdiction

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STAQDLFLXZLZBBX